Stock Insider Trading (from SEC Form 4)

MDVX / Medovex Corp. insiders include Lawson James Ronald JR (), and Thomas John C (), ANDREWS JAMES R M D (), Kullmann Patrick C (COO, PRESIDENT), Hennies Clyde A. (), Mogford Jon (), Betz Randal R (), PAPASAN LARRY W (), Sablowski Manfred (SENIOR VICE PRESIDENT), Crowne Jesse () Gorlin Jarrett S (CHIEF EXECUTIVE OFFICER), GORLIN STEVE (), Hills Thomas Edward (), Haufe Scott (), .

Medovex Corp. insider trades are found here. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

Job titles are listed as of the filing and may not be current. Click the link icon to see the full transaction history.

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.
File Date
Tran Date
Insider Code Shares Post Shares Percent
Tran Value Post Value Percent
2018-01-12 2018-01-11 Crowne Jesse Director
A 10,407 210,747 5.19 0.550 5,724
2018-01-02 2017-12-29 Betz Randal R Director
A 350 181,027 0.19 0.521 182
2017-12-19 2017-12-15 Thomas John C Director
P -6,000 115,960 -4.92 0.70 -4,200 81,172 -5.17
2017-12-19 2017-12-15 Mogford Jon Director
P -1,000 16,840 -5.61 0.70 -700 11,788 -5.94
2017-11-01 2017-10-30 ANDREWS JAMES R M D Director
A 12,821 131,348 10.82 1.17 15,001
2017-11-01 2017-10-30 Hennies Clyde A. Director
A 12,821 131,348 10.82 1.17 15,001
2017-11-01 2017-10-30 GORLIN STEVE
A 10,684 1,640,704 0.66 1.17 12,500
2017-11-01 2017-10-30 Haufe Scott Director
A 12,821 1,031,782 1.26 1.17 15,001
2017-11-01 2017-10-30 Lawson James Ronald JR Director
A 12,821 18,256 235.90 1.17 15,001
2017-11-01 2017-10-30 PAPASAN LARRY W Director
A 12,821 228,136 5.95 1.17 15,001
2017-06-20 2017-06-19 Gorlin Jarrett S CHIEF EXECUTIVE OFFICER, Director
P 20,000 662,172 3.11 0.90 18,000 595,955 3.02
2015-12-16 2015-12-15 Kullmann Patrick C COO, PRESIDENT
P 4,500 247,019 1.86 1.09 4,905 269,251 1.82
2015-11-25 2015-11-23 Hills Thomas Edward Director
P 10,000 111,788 9.82 1.399 13,990 156,391 8.95
2015-06-23 2015-06-22 Sablowski Manfred SENIOR VICE PRESIDENT
A 4,600 17,100 36.80 3.25 14,950
Open market or private purchase of non-derivative or derivative security
Open market or private sale of non-derivative or derivative security
Grant, award, or other acquisition of securities from the company (such as an option)
Conversion of derivative
Sale or transfer of securities back to the company
Payment of exercise price or tax liability using portion of securities received from the company
Gift of securities by or to the insider
Equity swaps and similar hedging transactions
Exercise or conversion of derivative security received from the company (such as an option)
A transaction voluntarily reported on Form 4
Other (accompanied by a footnote describing the transaction)

Related News Stories

Your Daily Pharma Scoop: AEterna Zentaris Gets FDA Nod, Valeant Finalizes Sprout Sale, Roche Gets EC Approval

2017-12-21 seekingalpha
Today we will focus on the much anticipated FDA decision on AEterna Zentaris’ (AEZS) Macrilen for diagnosis of adult growth hormone deficiency. (150-5)

Your Daily Pharma Scoop: Synergy's New CEO, AbbVie Data, TiGenix Changes

2017-12-21 seekingalpha
Today we will discuss an article on Synergy Pharmaceuticals (SGYP) by John Engle, titled, “Synergy’s New CEO: More Of The Same Or Change Of Course?” (496-2)

Medovex Corporation to Present at the 10th Annual LD Micro Main Event

2017-11-21 accesswire
LOS ANGELES, CA / ACCESSWIRE / November 21, 2017 / Medovex Corporation (OTCQB: MDVX), the developer of the DenerveX® System, a new and novel device designed for enduring relief of Facet Joint Syndrome related to chronic back pain, a non-addictive, non-opioid drug alternative capable of restoring a patient to a more normal and active lifestyle, today announced that it will be presenting at the 10th annual LD Micro Main Event on Tuesday, December 5, at 2:30PM PST / 5:30 PM EST at the Luxe Sunset Boulevard Hotel in Los Angeles, California. (19-1)

BRIEF-Medovex files for non-timely 10-Q

2017-11-14 reuters
* Medovex Corp files for non-timely 10-Q - SEC filing Source text: ( Further company coverage: (4-0)